
	Study Number: D8480C00067	<i>Confidential Document</i>
		<b>Trial Master File Zone:</b> Trial Management <b>Artifact:</b> 1.1.10

**Title/Reference:** A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)

**Topic:** Results not posted on the EudraCT registry.

**Summary:** The above mentioned study has been submitted to the authorities, however the study was stopped without any patients being recruited, therefore results will not be posted in the EudraCT registry.

, Sr GPD

  
Full Name, Position

\_\_\_\_\_  
Date